DAXOR CORP (DXR) Stock Price, Forecast & Analysis
NASDAQ:DXR • US2394671034
DXR Key Statistics, Chart & Performance
The current stock price of DXR is 11.86 USD. In the past month the price decreased by -2.87%. In the past year, price increased by 56.88%.
DXR Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to DXR. When comparing the yearly performance of all stocks, DXR is one of the better performing stocks in the market, outperforming 80.59% of all stocks.
DXR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DXR. While DXR seems to be doing ok healthwise, there are quite some concerns on its profitability.
DXR Financial Highlights
Over the last trailing twelve months DXR reported a non-GAAP Earnings per Share(EPS) of 0.41. The EPS increased by 22.53% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 2707.08% | ||
| ROA | 5.01% | ||
| ROE | 5.05% | ||
| Debt/Equity | 0.01 |
DXR Forecast & Estimates
5 analysts have analysed DXR and the average price target is 23.8 USD. This implies a price increase of 100.67% is expected in the next year compared to the current price of 11.86.
DXR Ownership
DXR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 20.26 | 202.318B | ||
| ISRG | INTUITIVE SURGICAL INC | 49.26 | 178.812B | ||
| SYK | STRYKER CORP | 25.62 | 148.172B | ||
| BSX | BOSTON SCIENTIFIC CORP | 21.94 | 113.97B | ||
| IDXX | IDEXX LABORATORIES INC | 44.32 | 52.44B | ||
| BDX | BECTON DICKINSON AND CO | 11.2 | 50.281B | ||
| EW | EDWARDS LIFESCIENCES CORP | 29.08 | 50.178B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.78 | 38.406B | ||
| RMD | RESMED INC | 20.87 | 37.332B | ||
| DXCM | DEXCOM INC | 29.08 | 28.639B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About DXR
Company Profile
Daxor Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. The company specializes in blood volume measurement technology focused on blood volume testing innovation. The company markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. The company has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Company Info
DAXOR CORP
107 Meco Lane
Oak Ridge TENNESSEE 10118 US
CEO: Joseph Feldschuh
Employees: 0
Phone: 18654250555
DAXOR CORP / DXR FAQ
Can you describe the business of DAXOR CORP?
Daxor Corp is a US-based company operating in Health Care Equipment & Supplies industry. The company is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. The company specializes in blood volume measurement technology focused on blood volume testing innovation. The company markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. The company has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Can you provide the latest stock price for DAXOR CORP?
The current stock price of DXR is 11.86 USD. The price decreased by -0.75% in the last trading session.
What is the dividend status of DAXOR CORP?
DXR does not pay a dividend.
How is the ChartMill rating for DAXOR CORP?
DXR has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the expected growth for DXR stock?
The Revenue of DAXOR CORP (DXR) is expected to grow by 5806.43% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is DAXOR CORP worth?
DAXOR CORP (DXR) has a market capitalization of 69.14M USD. This makes DXR a Micro Cap stock.
Can you provide the upcoming earnings date for DAXOR CORP?
DAXOR CORP (DXR) will report earnings on 2026-03-04.